Clinical Assessment: 55F, CKD5 on MHD ×3 months, Hb 6.5, Permacath, Upper Leg/Gluteal Pain ×2 weeks (static)

Differential Diagnosis — Upper Thigh/Gluteal Pain in MHD Patient

🔴 Priority 1 — Must Exclude First

1. Septic Arthritis / Psoas Abscess (Permacath-related Bacteremia)

• Permacaths carry a catheter-related bloodstream infection (CRBSI) rate far higher than fistulas — Staphylococcus aureus and gram-negatives are common.
• Hematogenous seeding can cause septic arthritis of the hip or psoas/iliopsoas abscess → presenting as groin/upper thigh/gluteal pain, often static and dull, with or without fever.
• This is the most dangerous cause. Pain near the glutes + permacath = rule out sepsis until proven otherwise.

2. Calciphylaxis (Calcific Uremic Arteriolopathy)

• Seen in dialysis patients, especially females with obesity, diabetes, warfarin use, high PTH, hyperphosphatemia.
• Can cause deep, ischemic pain in the buttock/thigh/flanks — often without early skin changes.
• Later: livedo reticularis, skin necrosis. Pain is often severe and disproportionate to exam.
• Though no skin ulcers are mentioned, early calciphylaxis is easily missed.

🟠 Priority 2 — Very Common in MHD

3. CKD-Mineral Bone Disorder (CKD-MBD) / Renal Osteodystrophy

• Secondary hyperparathyroidism → elevated PTH → osteitis fibrosa cystica → periosteal bone pain, fractures, subperiosteal resorption of bones. Pain is typically periarticular and in weight-bearing bones.
• Osteomalacia (low vitamin D / aluminum toxicity if older phosphate binders used) → diffuse aching bone pain, especially proximal muscles and pelvis.
• After only 3 months on dialysis, CKD-MBD was likely pre-existing and may now be symptomatic.
• PTH is often severely elevated at CKD Stage 5 onset of dialysis.

Brenner & Rector's The Kidney: "Changes in mineral metabolism and bone structure are detectable much earlier in CKD than previously considered… the plasma parathyroid hormone concentration rises exponentially when GFR falls below 45 mL/min/1.73 m²."

4. β₂-Microglobulin (Dialysis-Related) Amyloidosis

• Accumulation of β₂-microglobulin in CKD/dialysis → deposited in periarticular tissue, bone cysts, large joints.
• Classically carpal tunnel, but also causes destructive arthropathy of hips, shoulders, spine.
• Rare: immobile dermal/subdermal nodules affecting buttocks specifically reported.
• Usually develops after years on dialysis, but can occur earlier with high β₂-M accumulation.

Brenner & Rector: "Dialysis-related amyloidosis is secondary to β₂ microglobulin deposition… more common presentations involve carpal tunnel syndrome and destructive arthropathy. There have been rare reports of immobile dermal nodules… most often affecting the buttocks."

5. Avascular Necrosis (AVN) of the Femoral Head

• Risk factors in ESKD: steroid use, hypercoagulable state, vascular disease.
• Pain in groin/upper thigh/buttock, worsened with weight-bearing but can be static at rest.
• Confirmed by MRI (plain X-ray insensitive early).

🟡 Priority 3 — Other Considerations

Investigations

Urgent (Same Day)

Imaging

Laboratory (CKD-MBD Panel)

Management

1. Anemia (Hb 6.5 — Severe)

• Establish iron status first (Ferritin, TSAT):
  • If iron deficient (Ferritin <200 or TSAT <20%): IV iron sucrose or ferric carboxymaltose (preferred IV route in HD patients, given during dialysis session)
  • Start or optimize ESA (Erythropoietin alfa / darbepoetin alfa) per KDIGO: target Hb 10–11.5 g/dL (do NOT target >13 g/dL — risk of CV events)
  • If Hb critically low (e.g. symptomatic): consider blood transfusion cautiously (sensitization risk if transplant candidate)

KDIGO recommends ESA initiation when Hb <10 g/dL in dialysis patients, after excluding other correctable causes.

2. CKD-MBD Treatment

3. If Sepsis / CRBSI Suspected

• Start empiric antibiotics covering S. aureus while cultures pending:
  • Vancomycin (dose adjusted per pre-dialysis vancomycin level — give after dialysis session) + gram-negative coverage if febrile/shocked
• If confirmed bacteremia with permacath: remove catheter and place temporary femoral line or convert to AVF/AVG — permacath is a continued source of seeding
• If psoas abscess confirmed: CT-guided drainage + 4–6 weeks IV antibiotics

4. If Calciphylaxis Suspected

• Stop warfarin (if used) — substitute with heparin/LMWH
• Sodium thiosulfate (IV during HD, 25g TIW after dialysis) — primary treatment
• Optimize phosphate and PTH control
• Wound care specialist if skin lesions develop
• Low-calcium dialysate

5. If AVN Confirmed

• Orthopedic referral
• Non-weight-bearing for the hip
• Core decompression (early) or total hip replacement (late) depending on stage

6. Permacath — Long-term Access

• Plan urgent AVF/AVG creation — permacath is a high-risk access device; target transition to native fistula
• Meanwhile, strict catheter care (sterile technique, avoid catheter opening except during HD)

Summary Table

1. Draw blood cultures from the permacath AND peripherally — do this today.
2. Order the full CKD-MBD panel + inflammatory markers.
3. Pelvis/hip X-ray today, MRI pelvis (non-contrast) to plan urgently.
4. Address the Hb 6.5 — check iron stores and start IV iron if deficient; initiate/optimize ESA.
5. If any fever, rigors, or rising CRP: empiric vancomycin and consider early catheter removal.

Intradialytic Hypertension (IDH) — Comprehensive Clinical Guide

Why Does BP Rise at the End of Dialysis? — Pathophysiology

1. Volume Overload (Most Common — But Underdiagnosed)

• The dry weight target has not been truly reached — the patient appears clinically euvolemic but is still fluid-overloaded.
• Ultrafiltration removes fluid → expected BP drop. But if volume is still excessive, or the dry weight is set too high, BP rises instead.
• There is a "dialysis lag phenomenon": even after dry weight is correctly achieved, BP may remain elevated for days to weeks before normalizing. This misleads clinicians into thinking more fluid removal is futile.

Comprehensive Clinical Nephrology, 7th Ed: "Extracellular volume overload resulting from loss of sodium excretory capacity is the major cause of hypertension in dialysis patients… Reaching the optimal dry weight does not necessarily lead to normotension; a lag phase of some weeks can precede improvement."

2. High Dialysate Sodium / Sodium Modeling

• High Na⁺ dialysate (intended to prevent hypotension) creates a positive intradialytic sodium balance.
• This increases post-dialysis thirst → high interdialytic weight gain (IDWG) → recurrent volume overload → IDH.
• Sodium modeling (starting high ~150–154 mmol/L, then tapering) has been widely promoted but lacks definitive RCT benefit.

3. Renin-Angiotensin-Aldosterone System (RAAS) Overactivation

• Fluid removal during UF stimulates RAAS → angiotensin II rises → vasoconstriction → BP spike.
• Especially prominent in young patients with pre-existing hypertension and high baseline renin activity.
• This is the mechanism behind "dialysis-refractory hypertension" — BP doesn't come down despite fluid removal because vasoconstriction is driving it.

4. Sympathetic Nervous System Overactivity

• Uremia activates the SNS chronically. UF-triggered hypovalemia during dialysis further stimulates SNS → noradrenaline release → arterial vasoconstriction and elevated cardiac output.

5. Endothelial Dysfunction + Arterial Stiffness

• Chronic uremia impairs endothelial NO production → loss of vasodilatation.
• Arterial stiffness (common in long-term dialysis patients) amplifies pulse pressure and systolic BP.
• Elevated endothelin-1 (potent vasoconstrictor) is released during dialysis, especially with IV EPO use.

6. Erythropoiesis-Stimulating Agent (ESA) Use

• IV EPO → rapid rise in Hb → increased blood viscosity + elevated endothelin-1 → new or worsened hypertension in 20–30% of patients on IV EPO.
• More common with IV route versus subcutaneous.
• More pronounced with rapid hemoglobin correction.

7. Dialyzable Antihypertensive Medications

• ACE inhibitors (captopril, enalapril, lisinopril) and some β-blockers (atenolol, metoprolol) are dialyzed out during the session.
• BP rebounds in the last hour as the drug is cleared.
• This is one of the simplest and most correctable causes — switching to non-dialyzable agents solves it.

8. Non-Volume Causes (Box 42.1 — Comprehensive Clinical Nephrology)

What To Do: Stepwise Management

Step 1 — Acute Management During the Session (SBP >180 mmHg)

Step 2 — Reassess and Probe Dry Weight (Most Important Long-Term Step)

• Reduce dry weight target by 0.1–0.2 kg every 1–2 sessions, allowing time for the "lag phenomenon."
• Aim over 4–8 weeks of gradual reduction — do NOT aggressively drop dry weight in one session (causes intradialytic hypotension).
• Clinical signs that dry weight is still too high: persistent hypertension, lung crackles, raised JVP, cardiomegaly on CXR.
• Bioimpedance spectroscopy (BIS) — if available in your unit, use to objectively measure overhydration and guide dry weight targeting (RCT evidence is mixed but clinically helpful).
• Lung ultrasound (B-lines) — a quick, bedside tool to detect pulmonary congestion; useful pre/post dialysis.

DRIP trial (Dry-Weight Reduction in Hypertensive Hemodialysis Patients): Probing dry weight in patients with IDH was effective in normalizing both intradialytic and interdialytic hypertension.

Step 3 — Reduce Dialysate Sodium

Step 4 — Optimize Antihypertensive Medications

Switch Away from Dialyzable Drugs

Comprehensive Clinical Nephrology, 7th Ed: "Optimization of antihypertensive drug therapy… potentially including the use of minimally dialyzable or nondialyzable medications such as angiotensin receptor blockers, calcium channel blockers, clonidine, and carvedilol."

Best Drug Choices for Your Population

1. Carvedilol — targets SNS overactivity + endothelial dysfunction; vasodilatory properties; shown to reduce both intradialytic and ambulatory BP in IDH. First choice β-blocker.
2. Amlodipine — excellent in ESKD, not removed by dialysis, well tolerated.
3. ARB (candesartan/valsartan) — suppress RAAS; preferred over ACEi in dialysis (less risk of anaphylactoid reactions during HD with AN69 membranes).
4. Clonidine — useful add-on for SNS overactivity; can also be given as a patch (transdermal) for consistent levels.
5. Avoid ACE inhibitors given on dialysis days (unless switching to a non-dialyzable ACEI like ramipril given POST-dialysis or at night).

Step 5 — Adjust Dialysis Prescription

Step 6 — Address Contributing Factors

For Your Dialysis Unit (Unit-Wide IDH)

Summary — Priority Actions

Key clinical pearl: Most IDH is ultimately volume-mediated even when it doesn't look like it. The "lag phenomenon" means BP takes 2–4 weeks to normalize after true dry weight is achieved. Don't give up on ultrafiltration probing prematurely — and don't reflexively add more antihypertensives before the dry weight is correct.